Singapore companies that have listed on Nasdaq and where they are now is a question with nine very different answers. Grab Holdings turned profitable in 2025 after three years of losses and holds a market cap of roughly US$14 billion as of June 2026. Wave Life Sciences has been on the exchange since 2015 and is now in Phase 2a trials for an obesity drug. Ohmyhome sold its property business for $1. ASLAN Pharmaceuticals went into voluntary liquidation. Grindrod Shipping paid shareholders US$14.25 per share and walked away. Three other micro-cap listings are fighting compliance notices. This article tracks each company with current data and covers what the incoming SGX-Nasdaq dual-listing bridge means for Singapore investors.
The short answer is capital. SGX's daily trading volumes are a fraction of what a mid-sized Nasdaq stock sees in an afternoon. A Singapore technology company raising US$500 million can do so far more easily in the US, where institutional investors are comfortable valuing loss-making businesses on future revenue.
Nasdaq in particular attracts tech and biotech companies because of who follows those sectors there. A Singapore firm with a Southeast Asian growth story can pitch itself to US fund managers who already own similar businesses. That investor familiarity is hard to replicate on a smaller regional exchange.
A US listing also lets companies issue USD-denominated equity for acquisitions, pay employees with internationally recognized stock, and attract analysts who cover their global peers. The tradeoff is compliance cost: companies must file annual 20-F reports with the SEC, maintain Nasdaq listing standards on bid price and stockholders' equity, and absorb legal and accounting fees that smaller businesses often struggle to sustain.
If you want to buy shares in any of these companies, you need a brokerage with US market access. Our guide on buying US stocks as a Singapore investor covers how to open an account and what to watch on FX costs. Interactive Brokers is the most common choice for Singapore residents who trade US shares actively, though moomoo and Tiger Brokers also support Nasdaq-listed securities.
The table below covers all Singapore-headquartered companies that have listed on Nasdaq or NYSE since 2015. Sea Limited and PropertyGuru listed on NYSE, not Nasdaq, but both appear here because they feature in most discussions on this topic. The distinction matters and is explained in a dedicated section below.
| Company | Exchange | Ticker | Listed | Status (Jun 2026) | Key fact |
|---|---|---|---|---|---|
| Grab Holdings | Nasdaq | GRAB | Dec 2021 | Active | First profitable year 2025; market cap ~US$14.4B |
| Wave Life Sciences | Nasdaq | WVE | Nov 2015 | Active | Obesity drug WVE-007 in Phase 2a; market cap ~US$1.19B |
| MoneyHero Group | Nasdaq | MNY | Oct 2023 | Active | Down 50%+ from IPO; first profitable quarter Q4 2025 |
| Ohmyhome | Nasdaq | OMH | Mar 2023 | Active (pivoted) | Sold property unit for $1 Jun 2026; now digital marketing |
| Fitness Champs Holdings | Nasdaq | FCHL | 2025 | Active (at risk) | 30-for-1 reverse split May 2026; equity deficiency notice May 2026 |
| Trident Digital Tech | Nasdaq | TDTH | 2024-25 | Active (at risk) | Revenue US$161K TTM; net loss US$22.8M; bid price warning Oct 2025 |
| ASLAN Pharmaceuticals | Nasdaq | ASLN | 2018 | Delisted Jul 2024 | Voluntary liquidation; all employees terminated July 2024 |
| Grindrod Shipping | Nasdaq | GRIN | 2018 | Delisted Aug 2024 | Voluntary exit; shareholders received US$14.25 per share |
| Sea Limited | NYSE | SE | Oct 2017 | Active | Market cap ~US$51.75B; Q1 2026 revenue US$7.1B (+47%) |
| PropertyGuru | NYSE | PGRU | Mar 2022 | Delisted Dec 2024 | Taken private by EQT at US$6.70 per share |
Grab merged with Altimeter Growth Corp, a blank-check SPAC, and began trading on Nasdaq on December 2, 2021. The deal valued Grab at roughly US$40 billion at the SPAC reference price of US$10 per share. The stock opened lower on day one and kept falling through 2022 and 2023 as rising interest rates repriced growth companies globally and Grab continued burning cash.
The losses were structural. Grab spent heavily on subsidies to retain ride-hailing drivers and delivery partners across Southeast Asia, where it competes with Gojek, local taxi operators, and food delivery platforms in every market. Revenue was real but net income was deeply negative for three consecutive years after listing.
2025 changed the story. Grab reported full-year revenue of US$3.37 billion, up 21% from 2024, and net income of US$268 million. That is the first full year of profitability since listing. Q1 2026 revenue was US$955 million. The company has guided full-year 2026 revenue of US$4.04 to 4.10 billion with adjusted EBITDA of US$700 to 720 million.
As of June 26, 2026, the stock traded at around US$3.49 with a market cap of US$14.42 billion. Grab has 4.09 billion shares outstanding. That large share count is a direct consequence of the SPAC mechanism: warrants, founder shares, and the PIPE structure that funded the deal all add shares to the float. An investor who bought at the $10 SPAC price and held to June 2026 is still down roughly 65% in nominal terms, though the fundamental business has improved substantially.
The three current business segments are GrabTransport (ride-hailing), GrabFood (food delivery), and GFin (financial services including digital banking through GrabFinance and GXS Bank in Singapore).
Wave Life Sciences listed on Nasdaq in November 2015 as an RNA medicines company, initially focused on rare diseases including Duchenne muscular dystrophy and Huntington's disease. Its chemistry platform involves chemically modified RNA strands that can silence, restore, or edit gene expression.
The rare-disease programs did not progress to late-stage trials at the pace the company needed. Wave gradually shifted toward RNA editing and is now best known for WVE-007, an INHBE GalNAc-siRNA designed to reduce body fat in people with obesity or metabolic disease.
In December 2025, Wave published Phase 1 interim data from its INLIGHT clinical trial. A single 240mg dose of WVE-007 produced fat loss at three months comparable to GLP-1 drugs like semaglutide, without the muscle loss that GLP-1 users commonly experience. Wave moved into a Phase 2a multi-dose portion of INLIGHT in 2026, enrolling adults with higher BMI and cardiometabolic comorbidities. Additional trials of WVE-007 as an add-on to GLP-1 drugs and as a post-GLP-1 maintenance treatment were also initiated in 2026.
The stock traded at approximately US$5.83 on June 27, 2026, giving Wave a market cap of about US$1.19 billion. It is headquartered at Marina One East Tower, Singapore. The company has been public for over a decade and has never turned a full-year profit. The obesity pivot puts it in a much larger and better-funded clinical category than its original rare-disease focus, but Phase 2a data will take time to read out.
Between 2023 and 2025, four smaller Singapore companies listed on Nasdaq. None has achieved sustained profitability, and three are dealing with compliance notices.
MoneyHero listed on Nasdaq in October 2023 via a SPAC transaction. On its first day of trading the stock fell more than 50%, as investor appetite for SPAC-backed small-caps had largely evaporated by late 2023. MoneyHero runs a personal finance comparison service covering credit cards, loans, insurance, and savings accounts in Singapore, Hong Kong, Taiwan, and the Philippines.
By Q4 2025, the company posted its first adjusted EBITDA gain of US$0.7 million and net profit of US$0.5 million on quarterly revenue of US$20 million, up 27% from Q4 2024. It reports 7.4 million monthly active users. Whether that trajectory continues depends on whether revenue growth in four markets can outpace the overhead of running regulated financial comparison services across different jurisdictions.
Ohmyhome listed on Nasdaq in March 2023 as a Singapore proptech, providing property search and transaction services. In May 2026 it announced a restructuring. On June 17, 2026, it completed the sale of its property subsidiary for $1 to new owners. The subsidiary carried a negative net asset position of US$14.77 million as of March 31, 2026, so the $1 sale price was not a bargain for the buyer.
What remains listed on Nasdaq is a digital marketing business: content creation, online advertising, performance monitoring, and multi-channel campaign management. The company listed as a proptech and now operates as a digital marketing agency. Investors who bought Ohmyhome for its property platform own something entirely different.
Fitness Champs provides aquatic sports education in Singapore: swimming lessons, water polo, and lifesaving programs. It listed on Nasdaq in 2025 and raised US$5 million in a public offering in April 2026.
On May 4, 2026, Fitness Champs completed a 30-for-1 share consolidation to push its price above Nasdaq's US$1.00 minimum bid price requirement. Less than four weeks later, on May 26, 2026, Nasdaq sent a deficiency notice for a different reason: stockholders' equity was below the minimum threshold of US$2.5 million. Fixing the bid price problem does not fix the equity problem. The two notices are based on separate listing rules, and a company dealing with both simultaneously has a narrow path to maintained listing.
Trident is a Singapore-based IT services firm with a Nasdaq Capital Market listing. Over the trailing twelve months it generated US$161,000 in revenue, with a 51.2% gross margin on that figure. Its net loss over the same period was US$22.8 million. Those two numbers in the same paragraph tell the story.
In October 2025, Trident received a Nasdaq notification that its shares had closed below US$1.00 for 30 consecutive business days, opening a compliance period through April 27, 2026. The company works on digital identity projects and Web 3.0 infrastructure, but the gap between its operating costs and its revenue is extreme for a listed company.
Two Singapore-based companies left Nasdaq in 2024. They left for very different reasons, and the outcomes for shareholders were very different.
ASLAN listed on Nasdaq in 2018 as a Singapore-based clinical-stage biopharmaceutical company working in oncology and immunotherapy. On January 5, 2024, Nasdaq sent its first warning: ASLAN's American Depositary Shares had closed below US$1.00 for 30 consecutive business days, triggering a 180-day compliance window.
In July 2024, ASLAN implemented a ratio change for its ADS to push the price above $1.00. It held above that level for only five business days, short of the ten to twenty days required to satisfy the rule. On July 9, 2024, Nasdaq issued a formal delisting determination. ASLAN decided not to appeal. Its shares were suspended on July 19, 2024. The delisting was final the same day.
On July 17, 2024, ASLAN's sole operating subsidiary filed for voluntary liquidation. All employees were terminated immediately. This is the outcome when a clinical-stage company with no approved product cannot sustain the minimum capital position Nasdaq requires.
Grindrod Shipping operated a drybulk fleet under the Island View Shipping brand, with handysize and supramax vessels. It listed on Nasdaq Global Select Market in 2018. Major shareholder Taylor Maritime had signaled for years that it preferred a private structure.
In August 2024, Grindrod completed a Selective Capital Reduction under Section 78G of the Singapore Companies Act. All shares except those held by Good Falkirk (MI) were cancelled, and participating shareholders received US$14.25 per share in cash. Grindrod filed Form 25 with the SEC on August 16, 2024, and the delisting took effect before Nasdaq opened on August 26, 2024. This was an orderly, voluntary exit at a fixed cash price, not a compliance failure.
Sea Limited (NYSE: SE) is the most valuable company to emerge from Singapore's technology sector. It listed on the New York Stock Exchange in October 2017, not on Nasdaq. As of late June 2026, the stock trades at around US$95.43 with a market cap of approximately US$51.75 billion. In Q1 2026 Sea reported revenue of US$7.1 billion, up 47% year-on-year, with adjusted EBITDA exceeding US$1 billion for the first time. Shopee's gross merchandise value grew 30%, Monee's (formerly SeaMoney) loan book grew 71%, and Garena's bookings grew 20%.
PropertyGuru (NYSE: PGRU) also listed on the NYSE, not Nasdaq, in March 2022 via a SPAC merger. It operated Singapore's most widely used property search portal. In December 2024, EQT's BPEA Private Equity Fund VIII completed an acquisition at US$6.70 per share and PropertyGuru was delisted from the NYSE on December 13, 2024.
Both companies appear in most public discussions about Singapore companies on US exchanges because they are large and well known. Mixing them with Nasdaq listings creates confusion for investors who filter by exchange, so the distinction is worth keeping straight. If you want to hold Sea Limited through CPF Investment Scheme-eligible funds, check whether the brokerage or fund structure you use has NYSE access.
On November 19, 2025, SGX and Nasdaq announced a dual-listing bridge called the Global Listing Board (GLB). The idea is to let a company list on both exchanges simultaneously using a single set of disclosure documents and one financial statement prepared in either IFRS or US GAAP. Companies would only need to go through one review process rather than two.
The minimum market cap for GLB eligibility is S$2 billion. Companies listing through the bridge must also allocate at least 15% of the IPO value, or S$75 million (whichever is higher), to the Singapore tranche. That floor is designed to ensure Singapore investors have meaningful access to each listing.
SGX and MAS published consultation papers on January 9, 2026 and closed the consultation on February 8, 2026. The target launch remains mid-2026. If it proceeds on schedule, a company already listed on Nasdaq with a market cap above S$2 billion could add an SGX listing without rebuilding its disclosure documentation from scratch. The reverse applies too: a large SGX-listed company could access Nasdaq capital through the same framework.
For retail investors in Singapore, the main practical benefit is that companies trading on SGX are more easily held in standard local brokerage accounts and, for qualifying securities, through CPF Investment Scheme accounts. The FX conversion step disappears. Whether any current Nasdaq-listed Singapore company meets the S$2 billion floor matters here: Grab at US$14.4 billion would qualify comfortably. Wave Life Sciences at US$1.19 billion would not, at current prices.
No. Sea Limited (ticker: SE) is listed on the New York Stock Exchange, not Nasdaq. The two exchanges are separate US markets. Sea listed on the NYSE in October 2017 and remains listed there. As of June 2026 its market cap is approximately US$51.75 billion.
Grab listed via a SPAC merger at a reference price of US$10 per share in December 2021. The stock fell immediately and kept declining through 2022 and 2023 for two reasons. First, rising interest rates hit loss-making growth companies globally as investors moved to higher-discount-rate valuations. Second, Grab was genuinely burning through cash: it spent heavily on driver subsidies and expansion across Southeast Asia, running large net losses. The stock reached a low and recovered partially after Grab reported its first profitable year in 2025. As of June 2026 it trades around US$3.49.
ASLAN Pharmaceuticals was delisted from Nasdaq on July 19, 2024 after failing to meet the minimum bid price rule and the US$2.5 million stockholders' equity requirement. The company chose not to appeal the delisting determination. On July 17, 2024, its sole operating subsidiary filed for voluntary liquidation and terminated all employees immediately. ASLAN no longer operates as a going concern.
SGX and Nasdaq announced in November 2025 that they would create a dual-listing mechanism called the Global Listing Board, with a target launch around mid-2026. Under the framework, a company with a market cap of at least S$2 billion can list on both SGX and Nasdaq at the same time using a single set of disclosure documents and one financial statement. Singapore investors could then buy shares through local brokerages without needing USD accounts or USD FX conversion.
Grab Holdings is the largest by market cap among Singapore companies actively listed on Nasdaq, at approximately US$14.42 billion as of June 2026. Sea Limited is much larger at about US$51.75 billion, but it is listed on the NYSE, not Nasdaq.
Yes. Any Singapore resident with a brokerage that provides US market access can buy Nasdaq-listed shares including Grab (GRAB) and Wave Life Sciences (WVE). Interactive Brokers, moomoo, Tiger Brokers, and several other platforms available in Singapore support Nasdaq securities. You buy in USD, so the exchange rate affects your return. Shares held through these custodian brokers are not held directly in a CDP account.
Ohmyhome's property subsidiary had a negative net asset position of US$14.77 million as of March 31, 2026, meaning its liabilities exceeded its assets. Selling for $1 transferred those liabilities to the buyer. Ohmyhome's listed entity retained its Nasdaq shell and pivoted to digital marketing services. The sale closed on May 31, 2026, with the formal announcement on June 17, 2026.
This is general financial information for Singapore, not personal financial advice. Figures change — verify current rates against the official sources above before acting. See our full disclaimer.